Technical Analysis for GHRS - GH Research PLC

Grade Last Price % Change Price Change
B 10.95 13.94% 1.34
GHRS closed up 13.94 percent on Wednesday, November 20, 2024, on 1.49 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Expansion Breakout Bullish Swing Setup 0.00%
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 21 hours ago
Up 1% about 21 hours ago
Upper Bollinger Band Resistance about 21 hours ago
60 Minute Opening Range Breakdown 1 day ago
Possible NR7 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine

Is GHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.99
52 Week Low 5.05
Average Volume 63,557
200-Day Moving Average 10.15
50-Day Moving Average 7.87
20-Day Moving Average 8.67
10-Day Moving Average 9.28
Average True Range 0.80
RSI (14) 78.72
ADX 28.03
+DI 32.91
-DI 10.14
Chandelier Exit (Long, 3 ATRs) 8.69
Chandelier Exit (Short, 3 ATRs) 9.42
Upper Bollinger Bands 10.24
Lower Bollinger Band 7.11
Percent B (%b) 1.23
BandWidth 36.10
MACD Line 0.55
MACD Signal Line 0.36
MACD Histogram 0.1911
Fundamentals Value
Market Cap 569.63 Million
Num Shares 52 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -13.86
Price-to-Sales 0.00
Price-to-Book 1.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.34
Resistance 3 (R3) 13.12 12.10 12.94
Resistance 2 (R2) 12.10 11.50 12.21 12.80
Resistance 1 (R1) 11.53 11.12 11.82 11.75 12.67
Pivot Point 10.51 10.51 10.66 10.62 10.51
Support 1 (S1) 9.94 9.91 10.23 10.16 9.23
Support 2 (S2) 8.92 9.53 9.03 9.10
Support 3 (S3) 8.35 8.92 8.96
Support 4 (S4) 8.57